NCT04161391 2024-06-13
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Turning Point Therapeutics, Inc.
Phase 1/2 Terminated
Turning Point Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center